Literature DB >> 19130134

Evaluation of 47 soft tissue sarcoma resection specimens after isolated limb perfusion with TNF-alpha and melphalan: histologically characterized improved margins correlate with absence of recurrences.

Florian Grabellus1, Corinna Kraft, Sien-Yi Sheu, Peter Ebeling, Sebastian Bauer, Sven Lendemans, Kurt W Schmid, Georg Taeger.   

Abstract

BACKGROUND: Isolated limb perfusion (TM-ILP) is an effective limb-sparing treatment for primarily nonresectable soft tissue sarcomas (STS). Surgical margins of STS after ILP were yet not systematically studied.
METHODS: In 47 patients with nonresectable STS, TM-ILP with subsequent tumor resection was performed. Surgical margins were systematically analyzed by light microscopy using the TNM and the Enneking classification. Furthermore, margins were analyzed for tumor regression in terms of improved resectability. Results were correlated with clinical and pathological parameters.
RESULTS: Of 47 STS, 44 were classified as high-grade (93.6%) with a median tumor size of 10.0 cm. Primary limb-salvage rate was 85.1%. According to TNM resection margins were complete in 70.2% (R0) and incomplete in 29.8% (R1=21.3%, R2=8.5%). According to Enneking, 27.7% intralesional, 42.6% marginal, 21.3% wide, 2.1% radical, and 6.4% unclassifiable margins were found. Prior surgery and/or radiotherapy significantly decreased margin quality. Ten patients with incomplete resection (three intralesional, seven marginal) had no viable tumor at the plane of dissection, which was designated as "improved margins." Whereas those patients remained relapse free, five patients with viable tumor (not improved margins) at the resection margin had local recurrences. Poor margins were associated with local and distant recurrences and limited disease-specific survival.
CONCLUSION: TM-ILP is effective for achieving limb salvage. Histopathology of surgical margins demonstrates cases with so-called "improved margins" after TM-ILP, which are related to a better outcome even in intralesionally resected tumors. Improvement of margins should be further evaluated as a potential relevant prognostic parameter.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19130134     DOI: 10.1245/s10434-008-0277-4

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  6 in total

Review 1.  [Interdisciplinary treatment of soft tissue sarcoma of the extremities].

Authors:  J Jakob; T Henzler; B Kasper; A Marx; P Hohenberger
Journal:  Chirurg       Date:  2014-05       Impact factor: 0.955

2.  Chemotherapy influences the pseudocapsule composition in soft tissue sarcomas.

Authors:  Patrick W O'Donnell; J Carlos Manivel; Edward Y Cheng; Denis R Clohisy
Journal:  Clin Orthop Relat Res       Date:  2014-03       Impact factor: 4.176

3.  Radiotherapy for soft tissue sarcomas after isolated limb perfusion and surgical resection: essential for local control in all patients?

Authors:  Jan P Deroose; Jacobus W A Burger; Albertus N van Geel; Michael A den Bakker; Johannes S de Jong; Alexander M M Eggermont; Cornelis Verhoef
Journal:  Ann Surg Oncol       Date:  2010-11-04       Impact factor: 5.344

4.  Drug dosage in isolated limb perfusion: evaluation of a limb volume model for extremity volume calculation.

Authors:  Lars Erik Podleska; Thorsten Poeppel; Michael Herbrik; Lisa Dahlkamp; Florian Grabellus; Georg Taeger
Journal:  World J Surg Oncol       Date:  2014-04-01       Impact factor: 2.754

5.  Treatment of intimal sarcoma of peripheral veins.

Authors:  Javier López-Gómez; Erwin R Flores-Vázquez; Ma Alejandra Salazar-Álvarez; Rodrigo Y Adame; Dorian Y Garcia-Ortega; Mario Cuellar-Hübbe
Journal:  Int J Surg Case Rep       Date:  2017-01-16

6.  The pathologic response of resected synovial sarcomas to hyperthermic isolated limb perfusion with melphalan and TNF-α: a comparison with the whole group of resected soft tissue sarcomas.

Authors:  Benjamin Schwindenhammer; Lars Erik Podleska; Andrea Kutritz; Sebastian Bauer; Sien-Yi Sheu; Georg Taeger; Kurt Werner Schmid; Florian Grabellus
Journal:  World J Surg Oncol       Date:  2013-08-12       Impact factor: 2.754

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.